Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug3759 | Standard therapy of COVID-19 Wiki | 1.00 |
| drug3837 | Suspension of heat killed (autoclaved) Mycobacterium w Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D009164 | Mycobacterium Infections NIH | 0.50 |
| D016638 | Critical Illness NIH | 0.12 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The Post discharge after surgery Virtual Care with Remote Automated Monitoring technology (PVC-RAM) Trial is a multicentre, parallel group, superiority, randomized controlled trial to determine the effect of virtual care with remote automated monitoring (RAM) technology compared to standard care on days alive at home during the 30-day follow-up after randomization, in adults who have undergone semi-urgent (e.g., oncology), urgent (e.g., hip fracture), or emergency (e.g., ruptured abdominal aortic aneurysm) surgery. It will also determine, during the first 30 days, the effect of virtual care with RAM technology on several secondary outcomes, including: 1. hospital re-admission; 2. emergency department visit; 3. urgent-care centre visit; 4. acute-hospital care (i.e., a composite of hospital re-admission and emergency department or urgent-care centre visit) 5. brief acute-hospital care (i.e., acute-hospital care that lasts <24 hours); 6. all-cause hospital days; 7. medication error detection; 8. medication error correction; and 9. death. An additional secondary objective is to determine the effect of virtual care with RAM technology on pain at 7, 15, and 30 days and 6 months after randomization.
Description: Days alive at home are the number of days patients spend at their usual residence - be it a house or apartment, a group home or shelter, a seniors residence, or a nursing home - or at a community residence of a relative, friend, or acquaintance without, during that day, being admitted to a hospital or visiting an emergency department or urgent-care centre. Thus, patients lose days alive at home if 1. patients go to an emergency department or urgent-care centre; 2. they become inpatients at a hospital or rehabilitation or convalescence-care facility; or 3. they die.
Measure: Days alive at home Time: 30 Days (after randomization); 6 months (after randomization)Description: Medication errors include mistakes in medication prescribing, transcribing, dispensing, administering, or monitoring due to preventable events or actions taken by a patient, caregiver, or healthcare worker. Medication errors include: drug omission (i.e., patient did not take a drug they were supposed to take), drug commission (i.e., patient taking a drug they were not supposed to take), duration error, dosing error, frequency error, route error, and timing error. We will record all drug errors identified and also report whether they resulted in harm.
Measure: Medication error detection Time: Days 1, 7, 8, 15, 22 and 30 Days (after randomization in the intervention arm), 30 Days (after randomization in the standard care arm and collected on day 31)Description: Any medication error that is corrected.
Measure: Medication error correction Time: Days 1, 7, 8, 15, 22 and 30 Days (after randomization in the intervention arm), 30 Days (after randomization in the standard care arm and collected on day 31)Description: All cause mortality
Measure: Death Time: 30 Days (after randomization); 6 months (after randomization)Description: Assessed using the Brief Pain Inventory Short Form (BPI-SF)
Measure: Participant Pain Time: 7 Days (after randomization); 15 Days (after randomization); 30 Days (after randomization); 6 months (after randomization)Description: Composite of hospital re-admission and emergency department or urgent-care centre visit
Measure: Acute hospital care Time: 30 Days (after randomization); 6 months (after randomization)Description: If a patient is admitted to the hospital for any reason anytime between midnight and 23:59 on a given day, this will count as a day in hospital.
Measure: All-cause hospital days Time: 30 Days (after randomization); 6 months (after randomization)Description: Data on hospital re-admission, healthcare utilization, and costs of health service utilization will be obtained from the Institute for Clinical Evaluative Sciences (ICES) data repository
Measure: Health services utilization-related costs Time: 30 Days (after randomization); 6 months (after randomization)Description: Assessment performed using the Ambulatory Home Care Record
Measure: Patient level cost of recovery Time: 30 Days (after randomization)Description: Any surgical procedure undertaken for any reason (e.g., wound dehiscence, infection)
Measure: Re-operation Time: 30 Days (after randomization); 6 months (after randomization)Description: Arrythmia resulting in electrical cardioversion
Measure: Arrythmia resulting in electrical cardioversion Time: 30 Days (after randomization); 6 months (after randomization)Description: Acute renal failure resulting in dialysis
Measure: Acute renal failure resulting in dialysis Time: 30 Days (after randomization); 6 months (after randomization)Description: Patient intubated or put on bilevel positive airway pressure (BiPAP).
Measure: Respiratory failure Time: 30 Days (after randomization); 6 months (after randomization)Description: Infection
Measure: Infection Time: 30 Days (after randomization); 6 months (after randomization)Description: Positive history of delirium in hospital health records, positive 3D-CAM assessment, or FAM-CAM assessment. Assessments performed by telephone or in person.
Measure: Delirium Time: 30 Days (after randomization); 6 months (after randomization)Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports